Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Active Lupus Nephritis (SIRIUS-LN)
NCT05126277Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of ianalumab in lupus nephritis (LN), sponsored by Novartis. Started Jul 2022; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05126277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126277.